Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Coeptis Therapeutics Holdings (COEPW) Cost of Revenue (2021 - 2025)

Coeptis Therapeutics Holdings has reported Cost of Revenue over the past 3 years, most recently at $45157.0 for Q4 2025.

  • Quarterly results put Cost of Revenue at $45157.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $241969.0 (changed N/A YoY), and the annual figure for FY2025 was $180625.0, changed.
  • Cost of Revenue for Q4 2025 was $45157.0 at Coeptis Therapeutics Holdings, roughly flat from $45155.0 in the prior quarter.
  • Over the last five years, Cost of Revenue for COEPW hit a ceiling of $141518.0 in Q1 2021 and a floor of $8331.0 in Q4 2022.
  • Median Cost of Revenue over the past 3 years was $45157.0 (2025), compared with a mean of $67402.6.